Evidence map›Paper›PMID 33033569›Full record

ArticleWorld journal of hepatology2020

Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma.

Mohamed Saleh Ismail, Manal Hassan, Saira Aijaz Khaderi, Wael Ahmed Yousry, Maha Mohsen Kamal El-Din, Mohamed Mohamed Bahaa El-Din, Osama Aboelfotoh El Sayed, Ahmed Omar Kaseb, John Alan Goss, Fasiha Kanwal and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. [Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohamed Saleh IsmailDivision of Gastroenterology, Baylor College of Medicine, Houston, TX 77030, United States.
Manal HassanDivision of Gastroenterology, Baylor College of Medicine, Houston, TX 77030, United States.
Saira Aijaz KhaderiDivision of Gastroenterology, Baylor College of Medicine, Houston, TX 77030, United States.
Wael Ahmed YousryDepartment of Internal medicine, Gastroenterology and Hepatology, Ain Shams University, Cairo 11566, Egypt.
Maha Mohsen Kamal El-DinDepartment of Internal medicine, Gastroenterology and Hepatology, Ain Shams University, Cairo 11566, Egypt.
Mohamed Mohamed Bahaa El-DinDepartment of Surgery, Ain Shams University, Cairo 11566, Egypt.
Osama Aboelfotoh El SayedDepartment of Internal medicine, Gastroenterology and Hepatology, Ain Shams University, Cairo 11566, Egypt.
Ahmed Omar KasebDepartment of Gastrointestinal Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
John Alan GossDepartment of Surgery, Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX 77030, United States.
Fasiha KanwalDivision of Gastroenterology, Baylor College of Medicine, Houston, TX 77030, United States.
Prasun Kumar JalalDivision of Gastroenterology, Baylor College of Medicine, Houston, TX 77030, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent hepatitis C virus (HCV) infection of transplanted liver allografts is universal in patients with detectable HCV viremia at the time of transplantation. Direct-acting antiviral (DAA) therapy has been adopted as the standard of care for recurrent HCV infection in the post-transplant setting. However, there are insufficient data regarding its efficacy in liver transplant (LT) recipients with a history of hepatocellular carcinoma (HCC), and the risk of HCC recurrence after DAA therapy is unknown.

aimTo demonstrate predictors of DAA treatment failure and HCC recurrence in LT recipients.

methodsA total of 106 LT recipients given DAAs for recurrent HCV infection from 2015 to 2019 were identified (68 with and 38 without HCC). Descriptive statistics and logistic regression models were used to estimate the multivariate odds ratios and respective 95% confidence intervals for predictors of treatment failure and HCC recurrence.

resultsSix patients (6%) experienced DAA therapy failure post-LT and 100 (94%) had a sustained virologic response at follow-up week 12. A high alanine transaminase level > 35 U/L at treatment week 4 was a significant predictor of treatment failure. Relapse to pre-LT DAA therapy is a predictor of post-LT HCC recurrence,

conclusionDAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence.

Indexed as

Direct-acting antiviralHepatocellular carcinomaLiver transplantRecurrence

Identifiers

PMID33033569
PMCPMC7522560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.